Call Options

2 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2021

Nov 12, 2021

SELL
$21.86 - $34.77 $498,408 - $792,756
-22,800 Closed
0 $0
Q2 2021

Aug 13, 2021

BUY
$29.55 - $39.15 $673,740 - $892,620
22,800 New
22,800 $729,000

Others Institutions Holding RLMD

About RELMADA THERAPEUTICS, INC.


  • Ticker RLMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,608,500
  • Market Cap $77.8M
  • Description
  • Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...
More about RLMD
Track This Portfolio

Track Dld Asset Management, LP Portfolio

Follow Dld Asset Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dld Asset Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Dld Asset Management, LP with notifications on news.